S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
Log in
NASDAQ:ADVM

Adverum Biotechnologies Stock Forecast, Price & News

$11.30
-0.85 (-7.00 %)
(As of 03/3/2021 04:35 PM ET)
Add
Compare
Today's Range
$11.29
Now: $11.30
$12.43
50-Day Range
$11.37
MA: $12.93
$14.36
52-Week Range
$7.36
Now: $11.30
$26.98
Volume850,316 shs
Average Volume837,622 shs
Market Capitalization$1.10 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.72
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.
Adverum Biotechnologies logo

Headlines

Is ADVM A Good Stock To Buy According To Hedge Funds?
December 21, 2020 |  finance.yahoo.com
Adverum Biotechnologies Inc
December 19, 2020 |  bloomberg.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADVM
CUSIPN/A
Phone650-656-9323
Employees114
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$250,000.00
Book Value$2.71 per share

Profitability

Net Income$-64,490,000.00

Miscellaneous

Market Cap$1.10 billion
Next Earnings Date5/27/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.66 out of 5 stars

Medical Sector

275th out of 1,968 stocks

Biological Products, Except Diagnostic Industry

32nd out of 177 stocks

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
$11.30
-0.85 (-7.00 %)
(As of 03/3/2021 04:35 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

Is Adverum Biotechnologies a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Adverum Biotechnologies stock.
View analyst ratings for Adverum Biotechnologies
or view top-rated stocks.

What stocks does MarketBeat like better than Adverum Biotechnologies?

Wall Street analysts have given Adverum Biotechnologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Adverum Biotechnologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release its next quarterly earnings announcement on Thursday, May 27th 2021.
View our earnings forecast for Adverum Biotechnologies
.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) announced its quarterly earnings results on Sunday, February, 28th. The biotechnology company reported ($0.39) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.07.
View Adverum Biotechnologies' earnings history
.

How has Adverum Biotechnologies' stock price been impacted by Coronavirus (COVID-19)?

Adverum Biotechnologies' stock was trading at $9.26 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ADVM shares have increased by 22.2% and is now trading at $11.32.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ADVM?

10 brokers have issued 1-year price objectives for Adverum Biotechnologies' shares. Their forecasts range from $13.00 to $36.00. On average, they anticipate Adverum Biotechnologies' share price to reach $23.50 in the next twelve months. This suggests a possible upside of 107.6% from the stock's current price.
View analysts' price targets for Adverum Biotechnologies
or view top-rated stocks among Wall Street analysts.

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the following people:
  • Ms. Leone D. Patterson M.B.A., Pres (Age 58, Pay $874k)
  • Mr. Thomas Leung, Chief Financial Officer (Age 40, Pay $487.52k)
  • Dr. Aaron Osborne, Chief Medical Officer (Age 47, Pay $695.38k)
  • Dr. Laurent Fischer, CEO & Director (Age 57)
  • Ms. Angela Thedinga M.B.A., M.P.H., Chief Technology Officer (Age 39)
  • Ms. Myesha Lacy, VP of Investor Relations & Corp. Communications
  • Mr. Peter Soparkar J.D., Chief Legal Officer & Corp. Sec. (Age 50)
  • Ms. Dena House, VP of HR

What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?

3 employees have rated Adverum Biotechnologies CEO Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among Adverum Biotechnologies' employees.

Who are some of Adverum Biotechnologies' key competitors?

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.22%), Orbimed Advisors LLC (5.64%), Artal Group S.A. (2.56%), Dimensional Fund Advisors LP (1.75%), Price T Rowe Associates Inc. MD (1.70%) and Northern Trust Corp (1.08%). Company insiders that own Adverum Biotechnologies stock include James Paul Scopa, Laurent Fischer, Leone D Patterson, Mehdi Gasmi, Patrick Machado and Peter Soparkar.
View institutional ownership trends for Adverum Biotechnologies
.

Which major investors are selling Adverum Biotechnologies stock?

ADVM stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Assenagon Asset Management S.A., Citigroup Inc., Dimensional Fund Advisors LP, Barclays PLC, SG Americas Securities LLC, Credit Suisse AG, and Squarepoint Ops LLC. Company insiders that have sold Adverum Biotechnologies company stock in the last year include Leone D Patterson, and Mehdi Gasmi.
View insider buying and selling activity for Adverum Biotechnologies
or view top insider-selling stocks.

Which major investors are buying Adverum Biotechnologies stock?

ADVM stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Artal Group S.A., Price T Rowe Associates Inc. MD, Morgan Stanley, BlackRock Inc., JPMorgan Chase & Co., HarbourVest Partners LLC, and Massachusetts Institute of Technology. Company insiders that have bought Adverum Biotechnologies stock in the last two years include James Paul Scopa, Laurent Fischer, Patrick Machado, and Peter Soparkar.
View insider buying and selling activity for Adverum Biotechnologies
or or view top insider-buying stocks.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $11.32.

How much money does Adverum Biotechnologies make?

Adverum Biotechnologies has a market capitalization of $1.10 billion and generates $250,000.00 in revenue each year. The biotechnology company earns $-64,490,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does Adverum Biotechnologies have?

Adverum Biotechnologies employs 114 workers across the globe.

What is Adverum Biotechnologies' official website?

The official website for Adverum Biotechnologies is www.adverum.com.

Where are Adverum Biotechnologies' headquarters?

Adverum Biotechnologies is headquartered at 800 Saginaw Drive, Redwood City CA, 94063.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The biotechnology company can be reached via phone at 650-656-9323 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.